Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily. Earlier this summer, I showed up uninvited at a midtown Manhattan music venue, where ...

Praxis Precision Medicines will present late-stage epilepsy and movement disorder data at the AAN 2025 Annual Meeting in San Diego. Praxis Precision Medicines, Inc. announced its participation in the ...

Praxis Precision Medicines reported that its EMBOLD trial of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies was stopped early for efficacy, while also confirming FDA ...

Dryden Brown wants Praxis to be a crypto-city for tech bros and tastemakers. Just don’t ask for details. Praxis is part of a nebulous group of right-wing influencers who celebrate antiquity, ...

Praxis Precision Medicines, Inc. announced significant progress in its clinical pipeline, projecting six major study readouts across four programs in the next 12 months. The company plans to initiate ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Praxis is building a new city. Or, at least, that’s what the company’s website proclaims, in text overlaying an aerial rendering of ivory buildings tucked into the lush greenery of a coastal strip.

“Megan’s leadership has been a significant driver of Praxis’s success to date,” said Mr. Souza. “As COO, she is uniquely positioned to guide Praxis through its next phase, driving disciplined ...